Overview

177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC (EVOLUTION)

Status:
Not yet recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

This phase II study will investigate the activity and safety of radionuclide 177Lu-PSMA therapy versus 177Lu-PSMA in combination with Ipilimumab and Nivolumab in patients with metastatic castrate resistant prostate cancer (mCRPC).

Phase:

Phase 2

Details

Lead Sponsor:

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Collaborators:

Advanced Accelerator Applications
Bristol-Myers Squibb
Prostate Cancer Foundation of Australia
University of Sydney

Treatments:

177Lu-PSMA-617
Ipilimumab
Nivolumab